- Report
- April 2023
- 520 Pages
Global
From €3162EUR$3,295USD£2,734GBP
- Report
- June 2022
- 327 Pages
Global
From €3358EUR$3,500USD£2,904GBP
- Report
- May 2021
- 81 Pages
Global
From €816EUR$850USD£705GBP
- Report
- December 2018
- 438 Pages
Global
From €1319EUR$1,375USD£1,141GBP
€2639EUR$2,750USD£2,282GBP
- Report
- April 2022
- 301 Pages
Global
From €4006EUR$4,175USD£3,464GBP
- Report
- June 2021
- 185 Pages
Global
From €4006EUR$4,175USD£3,464GBP
- Report
- June 2020
- 150 Pages
North America
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- November 2022
- 408 Pages
Global
From €3454EUR$3,600USD£2,987GBP
- Book
- January 2022
- 400 Pages
- Book
- November 2017
- 628 Pages
Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more